Pfizer Goes On Offense With Celebrex: TV Ads, Study Proposal Stress Safety
Executive Summary
Pfizer is positioning Celebrex as the safest choice for pain therapy in its communications to physicians and consumers in the wake of the withdrawal of Merck's Vioxx
You may also be interested in...
Celebrex Heart Risk To Be Assessed By Cleveland Clinic In Pfizer-Funded Study
Pfizer's support for a massive study of Celebrex safety brings the drug maker together with researchers who have been urging the company to conduct additional trials; Pfizer approached Cleveland Clinic cardiovascular researchers about conducting the trial, which was announced Dec. 13
Celebrex Heart Risk To Be Assessed By Cleveland Clinic In Pfizer-Funded Study
Pfizer's support for a massive study of Celebrex safety brings the drug maker together with researchers who have been urging the company to conduct additional trials; Pfizer approached Cleveland Clinic cardiovascular researchers about conducting the trial, which was announced Dec. 13
Bextra Use Suspended By Kaiser; Celebrex Alzheimer’s Data Under Scrutiny
A decision by Kaiser Permanente physicians in California to stop prescribing Bextra demonstrates the challenges Pfizer must overcome as it seeks to reassure the public about the cardiovascular safety of COX-2 inhibitors